IDRA - Idera halts melanoma trial for cancer candidate after early positive results

The clinical-stage biotech Idera Pharmaceuticals (NASDAQ:IDRA) announced on Tuesday that investigators have decided to conclude a Phase 2 trial for the company’s cancer candidate tilsotolimod in melanoma after positive interim results. Idera (IDRA) shares have surged ~68% in the pre-market so far on above average volume. The investigator-sponsored INTRIM 1 trial was designed to study the synthetic Toll-like receptor 9 agonist among patients with localized, excised melanoma whose cancer haven’t spread elsewhere.   The study involved a single, intradermal injection of 8 mg tilsotolimod or saline placebo followed by re-excision and sentinel lymph node (SLN) biopsy after 7 – 10 days. According to topline data, SLN-positivity rates stood at 70% lower for patients who received tilsotolimod compared to those in the placebo arm. The placebo SLN+ rate was in the mid-40%s, the company said, adding that the statistical significance of the study topped the pre-specified p-value of 0.008. Adverse events included injection

For further details see:

Idera halts melanoma trial for cancer candidate after early positive results